{"id":4821,"date":"2014-08-19T09:00:00","date_gmt":"2014-08-19T09:00:00","guid":{"rendered":"https:\/\/breakthrought1d.eu\/nl\/nieuws\/pil-voor-minder-insuline-en-minder-schommelingen\/"},"modified":"2024-09-23T11:22:41","modified_gmt":"2024-09-23T11:22:41","slug":"pil-voor-minder-insuline-en-minder-schommelingen","status":"publish","type":"post","link":"https:\/\/breakthrought1d.eu\/nl\/nieuws\/pil-voor-minder-insuline-en-minder-schommelingen\/","title":{"rendered":"Pil voor minder insuline en minder schommelingen"},"content":{"rendered":"<p>Breakthrough T1D is een partnerschap aangegaan met Lexicon Pharmaceuticals, een bedrijf dat een nieuw medicijn, LX4211, heeft ontwikkeld. Samen staan de bedrijven aan de vooravond van de volgende klinische testfase waarin het medicijn samen met insuline wordt gebruikt bij mensen met Type 1 Diabetes.<\/p>\n<p>Het medicijn is een zogenaamde &#8216;inhibitor&#8217; van twee mechanismen die glucose opnemen in de darmen en nieren. LX4211 is bedoeld om de bloe<span class=\"text_exposed_show\">dsuikerwaardes te verlagen, waardoor minder insuline nodig is. Het medicijn zorgt mogelijk ook voor minder wisselende bloedsuikerwaardes.<br \/><\/span><span class=\"text_exposed_show\"><br \/><\/span><span class=\"text_exposed_show\"><\/span>In de volgende testfase krijgen 76 jongeren en jongvolwassenen met een HbA1c hoger dan 9% (75 mmol\/mol) het medicijn of een placebo, naast hun gebruikelijke hoeveelheid insuline. De testfase duurt 12 weken, waarbij wordt gekeken of de hoeveelheid insuline die de proefpersonen gebruiken daalt en of hun bloedsuikerwaardes stabieler blijven.<br \/><\/p>","protected":false,"raw":""},"excerpt":{"rendered":"<p>Breakthrough T1D is een partnerschap aangegaan met Lexicon Pharmaceuticals, een bedrijf dat een nieuw medicijn, LX4211, heeft ontwikkeld. Samen staan de bedrijven aan de vooravond van de volgende klinische testfase waarin het medicijn samen met insuline wordt gebruikt bij mensen met Type 1 Diabetes. Het medicijn is een zogenaamde &#8216;inhibitor&#8217; van twee mechanismen die glucose [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[184,187],"tags":[],"class_list":["post-4821","post","type-post","status-publish","format-standard","hentry","category-archief","category-behandelen"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v25.3 - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Pil voor minder insuline en minder schommelingen - Breakthrough T1D<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/breakthrought1d.eu\/nl\/nieuws\/pil-voor-minder-insuline-en-minder-schommelingen\/\" \/>\n<meta property=\"og:locale\" content=\"nl_NL\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Pil voor minder insuline en minder schommelingen - Breakthrough T1D\" \/>\n<meta property=\"og:description\" content=\"Breakthrough T1D is een partnerschap aangegaan met Lexicon Pharmaceuticals, een bedrijf dat een nieuw medicijn, LX4211, heeft ontwikkeld. Samen staan de bedrijven aan de vooravond van de volgende klinische testfase waarin het medicijn samen met insuline wordt gebruikt bij mensen met Type 1 Diabetes. Het medicijn is een zogenaamde &#8216;inhibitor&#8217; van twee mechanismen die glucose [&hellip;]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/breakthrought1d.eu\/nl\/nieuws\/pil-voor-minder-insuline-en-minder-schommelingen\/\" \/>\n<meta property=\"og:site_name\" content=\"Breakthrough T1D\" \/>\n<meta property=\"article:published_time\" content=\"2014-08-19T09:00:00+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2024-09-23T11:22:41+00:00\" \/>\n<meta name=\"author\" content=\"ylt-admin\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Geschreven door\" \/>\n\t<meta name=\"twitter:data1\" content=\"ylt-admin\" \/>\n\t<meta name=\"twitter:label2\" content=\"Geschatte leestijd\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minuut\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/breakthrought1d.eu\/nl\/nieuws\/pil-voor-minder-insuline-en-minder-schommelingen\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/breakthrought1d.eu\/nl\/nieuws\/pil-voor-minder-insuline-en-minder-schommelingen\/\"},\"author\":{\"name\":\"ylt-admin\",\"@id\":\"https:\/\/breakthrought1d.eu\/nl\/#\/schema\/person\/c141fde9814deb17e9eb392bdb6619a6\"},\"headline\":\"Pil voor minder insuline en minder schommelingen\",\"datePublished\":\"2014-08-19T09:00:00+00:00\",\"dateModified\":\"2024-09-23T11:22:41+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/breakthrought1d.eu\/nl\/nieuws\/pil-voor-minder-insuline-en-minder-schommelingen\/\"},\"wordCount\":138,\"publisher\":{\"@id\":\"https:\/\/breakthrought1d.eu\/nl\/#organization\"},\"articleSection\":[\"Archief\",\"Behandelen\"],\"inLanguage\":\"nl-NL\"},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/breakthrought1d.eu\/nl\/nieuws\/pil-voor-minder-insuline-en-minder-schommelingen\/\",\"url\":\"https:\/\/breakthrought1d.eu\/nl\/nieuws\/pil-voor-minder-insuline-en-minder-schommelingen\/\",\"name\":\"Pil voor minder insuline en minder schommelingen - Breakthrough T1D\",\"isPartOf\":{\"@id\":\"https:\/\/breakthrought1d.eu\/nl\/#website\"},\"datePublished\":\"2014-08-19T09:00:00+00:00\",\"dateModified\":\"2024-09-23T11:22:41+00:00\",\"breadcrumb\":{\"@id\":\"https:\/\/breakthrought1d.eu\/nl\/nieuws\/pil-voor-minder-insuline-en-minder-schommelingen\/#breadcrumb\"},\"inLanguage\":\"nl-NL\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/breakthrought1d.eu\/nl\/nieuws\/pil-voor-minder-insuline-en-minder-schommelingen\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/breakthrought1d.eu\/nl\/nieuws\/pil-voor-minder-insuline-en-minder-schommelingen\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/breakthrought1d.eu\/nl\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Pil voor minder insuline en minder schommelingen\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/breakthrought1d.eu\/nl\/#website\",\"url\":\"https:\/\/breakthrought1d.eu\/nl\/\",\"name\":\"Breakthrough T1D\",\"description\":\"Wij zetten ons in voor een toekomst zonder T1D\",\"publisher\":{\"@id\":\"https:\/\/breakthrought1d.eu\/nl\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/breakthrought1d.eu\/nl\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"nl-NL\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/breakthrought1d.eu\/nl\/#organization\",\"name\":\"Breakthrough T1D\",\"url\":\"https:\/\/breakthrought1d.eu\/nl\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"nl-NL\",\"@id\":\"https:\/\/breakthrought1d.eu\/nl\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/breakthrought1d.eu\/nl\/wp-content\/uploads\/2024\/11\/BTlogo.png\",\"contentUrl\":\"https:\/\/breakthrought1d.eu\/nl\/wp-content\/uploads\/2024\/11\/BTlogo.png\",\"width\":330,\"height\":141,\"caption\":\"Breakthrough T1D\"},\"image\":{\"@id\":\"https:\/\/breakthrought1d.eu\/nl\/#\/schema\/logo\/image\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\/\/breakthrought1d.eu\/nl\/#\/schema\/person\/c141fde9814deb17e9eb392bdb6619a6\",\"name\":\"ylt-admin\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"nl-NL\",\"@id\":\"https:\/\/breakthrought1d.eu\/nl\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/67a3317a8082bc0f586c2e46f82a1617530cf674f2027a1a7d60fdff63a2c3e8?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/67a3317a8082bc0f586c2e46f82a1617530cf674f2027a1a7d60fdff63a2c3e8?s=96&d=mm&r=g\",\"caption\":\"ylt-admin\"},\"sameAs\":[\"https:\/\/87.250.144.92\"],\"url\":\"https:\/\/breakthrought1d.eu\/nl\/nieuws\/author\/ylt-admin\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Pil voor minder insuline en minder schommelingen - Breakthrough T1D","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/breakthrought1d.eu\/nl\/nieuws\/pil-voor-minder-insuline-en-minder-schommelingen\/","og_locale":"nl_NL","og_type":"article","og_title":"Pil voor minder insuline en minder schommelingen - Breakthrough T1D","og_description":"Breakthrough T1D is een partnerschap aangegaan met Lexicon Pharmaceuticals, een bedrijf dat een nieuw medicijn, LX4211, heeft ontwikkeld. Samen staan de bedrijven aan de vooravond van de volgende klinische testfase waarin het medicijn samen met insuline wordt gebruikt bij mensen met Type 1 Diabetes. Het medicijn is een zogenaamde &#8216;inhibitor&#8217; van twee mechanismen die glucose [&hellip;]","og_url":"https:\/\/breakthrought1d.eu\/nl\/nieuws\/pil-voor-minder-insuline-en-minder-schommelingen\/","og_site_name":"Breakthrough T1D","article_published_time":"2014-08-19T09:00:00+00:00","article_modified_time":"2024-09-23T11:22:41+00:00","author":"ylt-admin","twitter_card":"summary_large_image","twitter_misc":{"Geschreven door":"ylt-admin","Geschatte leestijd":"1 minuut"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/breakthrought1d.eu\/nl\/nieuws\/pil-voor-minder-insuline-en-minder-schommelingen\/#article","isPartOf":{"@id":"https:\/\/breakthrought1d.eu\/nl\/nieuws\/pil-voor-minder-insuline-en-minder-schommelingen\/"},"author":{"name":"ylt-admin","@id":"https:\/\/breakthrought1d.eu\/nl\/#\/schema\/person\/c141fde9814deb17e9eb392bdb6619a6"},"headline":"Pil voor minder insuline en minder schommelingen","datePublished":"2014-08-19T09:00:00+00:00","dateModified":"2024-09-23T11:22:41+00:00","mainEntityOfPage":{"@id":"https:\/\/breakthrought1d.eu\/nl\/nieuws\/pil-voor-minder-insuline-en-minder-schommelingen\/"},"wordCount":138,"publisher":{"@id":"https:\/\/breakthrought1d.eu\/nl\/#organization"},"articleSection":["Archief","Behandelen"],"inLanguage":"nl-NL"},{"@type":"WebPage","@id":"https:\/\/breakthrought1d.eu\/nl\/nieuws\/pil-voor-minder-insuline-en-minder-schommelingen\/","url":"https:\/\/breakthrought1d.eu\/nl\/nieuws\/pil-voor-minder-insuline-en-minder-schommelingen\/","name":"Pil voor minder insuline en minder schommelingen - Breakthrough T1D","isPartOf":{"@id":"https:\/\/breakthrought1d.eu\/nl\/#website"},"datePublished":"2014-08-19T09:00:00+00:00","dateModified":"2024-09-23T11:22:41+00:00","breadcrumb":{"@id":"https:\/\/breakthrought1d.eu\/nl\/nieuws\/pil-voor-minder-insuline-en-minder-schommelingen\/#breadcrumb"},"inLanguage":"nl-NL","potentialAction":[{"@type":"ReadAction","target":["https:\/\/breakthrought1d.eu\/nl\/nieuws\/pil-voor-minder-insuline-en-minder-schommelingen\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/breakthrought1d.eu\/nl\/nieuws\/pil-voor-minder-insuline-en-minder-schommelingen\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/breakthrought1d.eu\/nl\/"},{"@type":"ListItem","position":2,"name":"Pil voor minder insuline en minder schommelingen"}]},{"@type":"WebSite","@id":"https:\/\/breakthrought1d.eu\/nl\/#website","url":"https:\/\/breakthrought1d.eu\/nl\/","name":"Breakthrough T1D","description":"Wij zetten ons in voor een toekomst zonder T1D","publisher":{"@id":"https:\/\/breakthrought1d.eu\/nl\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/breakthrought1d.eu\/nl\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"nl-NL"},{"@type":"Organization","@id":"https:\/\/breakthrought1d.eu\/nl\/#organization","name":"Breakthrough T1D","url":"https:\/\/breakthrought1d.eu\/nl\/","logo":{"@type":"ImageObject","inLanguage":"nl-NL","@id":"https:\/\/breakthrought1d.eu\/nl\/#\/schema\/logo\/image\/","url":"https:\/\/breakthrought1d.eu\/nl\/wp-content\/uploads\/2024\/11\/BTlogo.png","contentUrl":"https:\/\/breakthrought1d.eu\/nl\/wp-content\/uploads\/2024\/11\/BTlogo.png","width":330,"height":141,"caption":"Breakthrough T1D"},"image":{"@id":"https:\/\/breakthrought1d.eu\/nl\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/breakthrought1d.eu\/nl\/#\/schema\/person\/c141fde9814deb17e9eb392bdb6619a6","name":"ylt-admin","image":{"@type":"ImageObject","inLanguage":"nl-NL","@id":"https:\/\/breakthrought1d.eu\/nl\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/67a3317a8082bc0f586c2e46f82a1617530cf674f2027a1a7d60fdff63a2c3e8?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/67a3317a8082bc0f586c2e46f82a1617530cf674f2027a1a7d60fdff63a2c3e8?s=96&d=mm&r=g","caption":"ylt-admin"},"sameAs":["https:\/\/87.250.144.92"],"url":"https:\/\/breakthrought1d.eu\/nl\/nieuws\/author\/ylt-admin\/"}]}},"_links":{"self":[{"href":"https:\/\/breakthrought1d.eu\/nl\/wp-json\/wp\/v2\/posts\/4821","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/breakthrought1d.eu\/nl\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/breakthrought1d.eu\/nl\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/breakthrought1d.eu\/nl\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/breakthrought1d.eu\/nl\/wp-json\/wp\/v2\/comments?post=4821"}],"version-history":[{"count":1,"href":"https:\/\/breakthrought1d.eu\/nl\/wp-json\/wp\/v2\/posts\/4821\/revisions"}],"predecessor-version":[{"id":7190,"href":"https:\/\/breakthrought1d.eu\/nl\/wp-json\/wp\/v2\/posts\/4821\/revisions\/7190"}],"wp:attachment":[{"href":"https:\/\/breakthrought1d.eu\/nl\/wp-json\/wp\/v2\/media?parent=4821"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/breakthrought1d.eu\/nl\/wp-json\/wp\/v2\/categories?post=4821"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/breakthrought1d.eu\/nl\/wp-json\/wp\/v2\/tags?post=4821"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}